Tag: celsion

April 9, 2018

Data Monitoring Committee Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (DMC) for the Company’s...
March 27, 2018

Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results

Celsion (NASDAQ:CLSN), an oncology drug development company, announced financial results for the year ended December 31, 2017 and provided an update...
January 18, 2018

Celsion Corporation Provides Corporate Update and 2018 Outlook

Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a year-end 2017 corporate review and announced clinical progress for two...